NCT03793361已完成2 期
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 127
- 试验地点
- 20
- 主要终点
- To assess the efficacy of regorafenib compared to placebo
研究概览
简要总结
Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib® to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line chemotherapy.
详细描述
Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors:
- Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype
- Response to doxorubicin-based chemotherapy: partial response versus stable disease
- Centers
The treatment will be administrated as long as it appears beneficial. Evaluations will be made every 8 weeks until 6 months and then every 3 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Histologically proven soft tissue sarcoma including leiomyosarcoma, synovial sarcoma and other sarcomas
- •Patients in partial response or stable disease after 6 cycles of doxorubicin-based first-line chemotherapy for metastatic/locally advanced soft tissue sarcoma
- •Metastatic/locally advanced disease not amenable to surgical resection with curative intent
- •Eastern Cooperative Oncology Group (ECOG) Performance Status =0 or 1
- •Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST 1.
- •Available tumor tissue for translational research program
- •Adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation:
- •Absolute neutrophil count (ANC) ≥1,500/mm3
- •Platelets ≥100,000/mm3
- •Hemoglobin ≥9.0 g/dL
- •Serum creatinine ≤1.5 x upper limit of normal (ULN)
- •Glomerular filtration rate (GFR) ≥30 ml/min/1.73m2
- •AST and ALT ≤2.5 x ULN ( ≤5.0 × ULN for patients with liver involvement of their cancer)
- •Bilirubin ≤1.5 X ULN
- •Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN with liver involvement of their cancer)
- •Lipase ≤1.5 x ULN
- •Spot urine must not show 1+ or more protein in urine or the patient will require a repeat urine analysis. If repeat urinanalysis shows 1+ protein or more, a 24-hour urine collection will be required and must show total protein excretion <1000 mg/24 hours
- •INR/PTT ≤1.5 x ULN (Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care.)
- •Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care.
- •Recovery to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure related toxicity (except alopecia, anemia, and hypothyroidism).
- •In the assessment of the investigator, patients are able to comply with study requirements
- •Signed, IRB-approved written informed consent
- •Patient covered by the French "Social Security" regime
排除标准
- •Prior adjuvant or neoadjuvant chemotherapy not allowing at least 6 cycles of doxorubicin-based chemotherapy at metastatic stage
- •Complete response to 1st line chemotherapy for metastatic/locally advanced soft tissue sarcoma
- •Disease progression during the 1st line of chemotherapy
- •Time interval between the last cycle of doxorubicin-based chemotherapy superior to 8 weeks
- •Primary bone sarcoma
- •All forms of liposarcoma
- •Some particular histologic types, i.e., PNET/Ewing, alveolar or embryonal rhabdomyosarcoma, Perivascular epithelioid cell sarcoma (PECoMA), low grade endometrial stromal tumor, desmoid tumor
- •Prior treatment with tyrosine kinase inhibitor
- •Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator
- •Pregnant or breastfeeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of Day 1 of treatment
- •Active cardiac disease including any of the following: Congestive heart failure (New York Heart Association [NYHA]) ≥Class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- •Uncontrolled hypertension (Systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management)
- •Arterial or venous thrombotic or embolic events such as myocardial infarction, cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months of starting on study drug
- •Any hemorrhage or bleeding event > Grade 4 within 4 weeks of start of treatment
- •Ongoing infection >Grade 2 according to NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v. 5.0)
- •Known history of human immunodeficiency virus (HIV) infection
- •Known history of chronic hepatitis B or C
- •Patients with seizure disorder requiring medication
- •History of organ allograft
- •Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event > Grade 4 within 4 weeks of start of treatment
- •Non-healing wound, ulcer, or bone fracture
- •Renal failure requiring hemo- or peritoneal dialysis
- •Dehydration according to NCI-CTC v 4.0 Grade >1
- •Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
- •Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
- •Inability to swallow oral medications, Any mal-absorption condition
- •Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)
研究组 & 干预措施
Arm A
Experimental
Regorafenib
干预措施: Regorafenib (Drug)
Arm B
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
To assess the efficacy of regorafenib compared to placebo
时间窗: from the date of randomization to the date of first observed disease progression (according to RECIST 1.1 criteria) or death from any cause, up to 12 months after the beginning of the treatment
Progression-Free Survival will be measured from the date of randomization until the date of radiological progression (according to RECIST 1.1 criteria) or death (if death occurs before progression).
次要结局
- To assess the safety of regorafenib(Baseline, every 4 weeks, up to 12 months after the beginning of the treatment)
- To assess the relative benefit/risk ratio(up to 12 months)
- To assess the efficacy of regorafenib compared to placebo(from the date of randomization to the date of death from any cause, up to 12 months after the beginning of the treatment)
- To assess the efficacy of regorafenib compared to placebo(from the date of randomization to the date of death from any cause)
- To assess the efficacy of regorafenib compared to placebo(from the date of randomization to the date of first observed disease progression (according to RECIST 1.1) or death from any cause, up to 12 months after the beginning of the treatment)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTsGastrointestinal Stromal Tumors (GISTs)NCT02889328Asan Medical Center25
进行中（未招募）
1 期
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.Patient with metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10010028Term: Colorectal cancer Duke's DSystem Organ Class: 100000004864EUCTR2016-002222-37-DKHerlev og Gentofte Hospital60
已完成
3 期
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)Gastrointestinal Stromal TumorsNCT01271712Bayer199
已完成
3 期
Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyColorectal NeoplasmsNCT01584830Bayer204
进行中（未招募）
2 期
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerBRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal AdenocarcinomaMetastatic Colorectal AdenocarcinomaNRAS Gene Mutation NegativeStage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8NCT04117945Academic and Community Cancer Research United22